---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-24-000011"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:57:30.066719+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Praxis licenses ulixacaltamide to Tenacia for Greater China; PRAX-628 Phase 2a PPR data positive; $81.3M cash

## Summary
- Entered exclusive collaboration with Tenacia Biotechnology for ulixacaltamide in essential tremor in Greater China.
- Issued 443,253 shares to BCPE (Bain Capital affiliate) at $22.5605/share (~20% premium) for $10M aggregate.
- Preliminary cash and equivalents as of Dec 31, 2023: $81.3 million.
- PRAX-628 Phase 2a PPR study: preliminary analysis of 15 mg cohort exceeded expectations; full data Q1 2024.

## SEC filing metadata
- accession: 0001689548-24-000011
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000011/0001689548-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000011/prax-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-24-000011
- JSON: https://secwatch.observer/filing/0001689548-24-000011.json
- Plain text: https://secwatch.observer/filing/0001689548-24-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.